PTEN and melanoma: The discrepancy between the percentage of PTEN-loss cases, as analyzed by IHC, and the high percentage of PD-L1 and VISTA+ lymphocytes (28% vs. 61% and 67%, respectively) in melanoma biopsies at progression suggests that the PTEN protein might be inactive, albeit present, in this context.